人ProIGF-I EB（104 - 123）抗血清是通過用衍生自與白喉類毒素連接的人ProIGF-I EB的21個氨基酸的肽免疫兔來制備的。 該肽位于195個氨基酸的ProIGF-I EB的E結構域內，其來源于人igf-1基因的選擇性剪接。 抗血清識別ProIGF-I EB，但不識別ProIGF-I EA、ProIGF-I EC、成熟IGF-I或IGF-II。 肽序列分析表明，由于igf-1基因的選擇性剪接，它可以識別多種非人靈長類動物中的ProIGF-I EB相關蛋白，但不能識別許多其它物種。 與牛、豬和犬種中ProIGF-I變體的相似區域有顯著的同源性，提示其可能有效。 Human ProIGF-I EB (104-123) antiserum was prepared by immunising rabbits with a 21 amino acid peptide derived from human ProIGF-I EB linked to diphtheria toxoid. The peptide is located within the E domain of the 195 amino acid ProIGF-I EB, derived from alternative splicing of the human igf-1 gene. The antiserum recognises ProIGF-I EB but not ProIGF-I EA, ProIGF-I EC, mature IGF-I or IGF-II. Peptide sequence analysis suggest it may recognise ProIGF-I EB related proteins in a range of non-human primates but not many other species due to alternative splicing of the igf-1 gene. There is significant homology to similar regions of ProIGF-I variants in bovine, porcine and canine species to suggest it may be effective.
GroPep Bioreagents公司總部位于澳大利亞，成立于1990年，致力于向廣大科研院所、生物技術及制藥公司開發、生產和銷售細胞培養級的活性生長因子（主要集中在胰島素樣生長因子（IGF）領域）、抗體及相關蛋白試劑，現有產品超過100多個，同時在世界范圍內均設有分銷商。公司在分子生物領域、發酵學及重組蛋白和單抗制備方面具有豐富的經驗，在制造工藝方面，擁有大量專利技術，GroPep目前已通過AS/NZS ISO 9001:2016質量管理體系認證。
